Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 21.30
HPTX's Cash to Debt is ranked higher than
76% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. HPTX: 21.30 )
HPTX' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 21.3

Equity to Asset 0.50
HPTX's Equity to Asset is ranked higher than
63% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. HPTX: 0.50 )
HPTX' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.87
Current: 0.5

0.5
0.87
F-Score: 6
Z-Score: 2.38
M-Score: 7.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 20.43
HPTX's Operating margin (%) is ranked higher than
92% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. HPTX: 20.43 )
HPTX' s 10-Year Operating margin (%) Range
Min: -31.79   Max: -31.79
Current: 20.43

Net-margin (%) 21.30
HPTX's Net-margin (%) is ranked higher than
93% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. HPTX: 21.30 )
HPTX' s 10-Year Net-margin (%) Range
Min: 39.4   Max: 39.4
Current: 21.3

ROE (%) 15.38
HPTX's ROE (%) is ranked higher than
92% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. HPTX: 15.38 )
HPTX' s 10-Year ROE (%) Range
Min: 21.58   Max: 21.58
Current: 15.38

ROA (%) 11.23
HPTX's ROA (%) is ranked higher than
93% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. HPTX: 11.23 )
HPTX' s 10-Year ROA (%) Range
Min: -722.57   Max: 17.17
Current: 11.23

-722.57
17.17
ROC (Joel Greenblatt) (%) 1306.05
HPTX's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. HPTX: 1306.05 )
HPTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -275357.89   Max: -2724.26
Current: 1306.05

-275357.89
-2724.26
» HPTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HPTX Guru Trades in Q1 2013

RS Investment Management 74,900 sh (New)
Steven Cohen 125,000 sh (New)
Louis Moore Bacon 15,000 sh (New)
» More
Q2 2013

HPTX Guru Trades in Q2 2013

Steven Cohen Sold Out
Louis Moore Bacon Sold Out
RS Investment Management 73,078 sh (-2.43%)
» More
Q3 2013

HPTX Guru Trades in Q3 2013

RS Investment Management Sold Out
» More
Q2 2014

HPTX Guru Trades in Q2 2014

Jim Simons 34,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with HPTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.50
HPTX's P/E(ttm) is ranked higher than
94% of the 987 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 26.50 )
HPTX' s 10-Year P/E(ttm) Range
Min: 18.87   Max: 177.55
Current: 26.5

18.87
177.55
P/B 3.26
HPTX's P/B is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. HPTX: 3.26 )
HPTX' s 10-Year P/B Range
Min: 3.09   Max: 5.76
Current: 3.26

3.09
5.76
P/S 5.66
HPTX's P/S is ranked higher than
83% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. HPTX: 5.66 )
HPTX' s 10-Year P/S Range
Min: 5.36   Max: 516.4
Current: 5.66

5.36
516.4
PFCF 15.11
HPTX's PFCF is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 15.11 )
HPTX' s 10-Year PFCF Range
Min: 14.32   Max: 40.65
Current: 15.11

14.32
40.65
EV-to-EBIT 19.03
HPTX's EV-to-EBIT is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 19.03 )
HPTX' s 10-Year EV-to-EBIT Range
Min: -194.9   Max: 25.9
Current: 19.03

-194.9
25.9
Current Ratio 3.38
HPTX's Current Ratio is ranked higher than
71% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. HPTX: 3.38 )
HPTX' s 10-Year Current Ratio Range
Min: 0.11   Max: 11.32
Current: 3.38

0.11
11.32
Quick Ratio 3.31
HPTX's Quick Ratio is ranked higher than
72% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. HPTX: 3.31 )
HPTX' s 10-Year Quick Ratio Range
Min: 0.11   Max: 11.27
Current: 3.31

0.11
11.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.39
HPTX's Price/Median PS Value is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. HPTX: 0.39 )
HPTX' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 36.37
Current: 0.39

0.43
36.37
Earnings Yield (Greenblatt) 5.30
HPTX's Earnings Yield (Greenblatt) is ranked higher than
79% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. HPTX: 5.30 )
HPTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.9   Max: 5
Current: 5.3

3.9
5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0HY.Germany
Hyperion Therapeutics Inc was incorporated under the laws of the State of Delaware in November 2006. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company's product candidate, Ravicti (glycerol phenylbutyrate), is designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. It is developing Ravicti to treat two different diseases in which blood ammonia is elevated: the prevalent urea cycle disorders, or UCD, and hepatic encephalopathy, or HE. UCD are inherited rare genetic diseases caused by a deficiency of one or more enzymes or protein transporters that constitute the urea cycle, which in a healthy individual removes ammonia through the conversion of ammonia to urea. HE may develop in some patients with liver scarring, known as cirrhosis, or acute liver failure and is a chronic disease which fluctuates in severity and may lead to serious neurological damage. The Company's strategy is to commercialize a product portfolio, including Ravicti, for the treatment of UCD and to develop Ravicti for the treatment of HE and other indications. Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price; Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd's worldwide rights to BUPHENYL and, subject to certain conditions, AMMONUL.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK